Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.

Slides:



Advertisements
Similar presentations
Practical implementation of the ADVANCE results in real life Davide Carvalho Centro Hospitalar S. João, University of Porto Medical School, Portugal 12.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Benefits of intensive multiple risk factor intervention.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
The concept of Diabetes & CV risk: A lifetime risk challenge
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Glucose Targets for Patients with Diabetes: 2011 Irl B. Hirsch, M.D. Professor of Medicine University of Washington School of Medicine.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Randomized, double-blind, multicenter, controlled trial.
Translating Clinical Trials Into Clinical Practice Cliff Bailey on behalf of the Global Partnership for Effective Diabetes Management This slideset was.
Blood glucose: is lower better for diabetic patients?
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Clinical Outcomes with Newer Antihyperglycemic Agents
Glycemic Control in Type 2 Diabetes: How Tight is Too Tight? Frederick L. Brancati, MD, MHS Professor of Medicine & Epidemiology Director, Division of.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Glycemic Control: When the Lower is Not the “Better”?
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
A Diabetes Outcome Progression Trial
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes type 2 Landmark Outcomes Trials
The SPRINT Research Group
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Insulin Delivery Systems Atlanta Diabetes Associates
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
TNT: Baseline and final LDL cholesterol levels
Macrovascular Complications Microvascular Complications
Systolic Blood Pressure Intervention Trial (SPRINT)
on behalf of the LEADER Trial Steering Committee and Investigators
366 میلیون نفر در جهان مبتلا به دیابت هستند.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Diabetes Journal Club March 17, 2011
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
Characteristics of the Patients at Baseline*
Glycated Hemoglobin Levels (A1C)
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Epidemiology suggests high glucose is toxic

Blood glucose and CV risk N = 17,869 men, aged 40–64 years; follow-up 33 years Brunner EJ et al. Diabetes Care. 2006;29: *Relative to baseline group of all men with blood glucose <83 mg/dL 83 mg/dL OGTT blood glucose (mg/dL) CHD mortality (log hazard ratios)*

Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B), adjusted for age, sex, and race and plotted on the log scale. All adjusted relative hazards are centered at hemoglobin A1c (HbA1c) = 5.2%, and the graphed lines are shown for the fifth to 95th percentiles of HbA1c level. The solid black line in A is from a single-knot linear spline model (knot at HbA1c = 4.6%). The dotted gray line is from a linear spline model with knots at the quintiles of HbA1c. In B, the solid black line is from a linear model; the gray dotted line is from a linear spline model with knots at the quintiles of HbA1c level. The normal range for HbA1c in persons without diabetes (4%-6%) is indicated by the dotted vertical lines in A. The current target for glycemic control in persons with diabetes (HbA1c = 7%) is indicated by the vertical dotted line in B. Arch Intern Med Sep 12;165(16): Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B)

Diabetic milleu is a toxic soup with hyperglycemia, lipids, oxidative stress and combination of drugs….

Effect of postprandial hyperglycemia on the arterial wall Meal Hyperglycemia Hyperlipidemia Haller H. Diab Res Clin Pract 1998;40:S43–S49. Oxidative stress Endothelial damage Atherosclerosis

Adjusted Hazard Ratios for Self-Reported Diagnosed Diabetes and Coronary Heart Disease, Ischemic Stroke, and Death from Any Cause, According to the Baseline Glycated Hemoglobin Value. Selvin E et al. N Engl J Med 2010;362:

BMJ Jan 14;332(7533):73-8. Epub 2005 Dec 21

Lowering glucose in a diabetic patient decreases macro and microvascular complications.

Glucose Control Study Summary UKPDS The intensive glucose control policy maintained a lower HbA 1c by mean 0.9 % over a median follow up of 10 years from diagnosis of type 2 diabetes with reduction in risk of: 12%for any diabetes related endpointp= %for microvascular endpoints p= %for myocardial infarctionp= %for cataract extractionp= %for retinopathy at twelve yearsp= %for albuminuria at twelve years p=

Kaplan-Meier Curves for Four Prespecified Aggregate Clinical Outcomes Holman RR et al. N Engl J Med 2008;359:

DCCT/EDIC Study Research Group. N Engl J Med. 2005;353: DCCT/EDIC: Intensive glucose control reduces long-term CV risk  42% (95% CI 9%–63%) P = 0.02  57% (95% CI 12%–79%) P = 0.02 Cumulative incidence of any first CV event Cumulative CV death, nonfatal MI, stroke Time (years) Conventional 52 events Intensive 31 events Conventional 25 events Intensive 11 events N = 1441 with type 1 diabetes

Glucose Control at Baseline and during Follow-up, According to Glucose-Control Strategy The ADVANCE Collaborative Group. N Engl J Med 2008;358:

Cumulative Incidences of Events, According to Glucose-Control Strategy The ADVANCE Collaborative Group. N Engl J Med 2008;358:

Normoglycemia does not necessarily mean increased hypoglycemia

Hypoglycemia is a side effect of treatment not of good metabolic control

Annual Rates of Severe Hypoglycemia According to Treatment Assignment and Adverse Clinical Outcomes among Patients with Severe Hypoglycemia. Zoungas S et al. N Engl J Med 2010;363:

How about ACCORD ?

Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause. The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:

Spline curves displaying the risk of all-cause mortality with the two treatment strategies over the range of average A1C from 6.0 to 9.0%. The curves represent the linear part of the proportional hazards models derived from values for intervals of average A1C from model 3. For clarity, the figure omits values 9%; ∼ 5% of deaths are excluded from this plot at the lower end and also at the higher end of the A1C range, but these data are included in the models. The bold orange line represents the intensive treatment strategy group, the bold blue line represents the standard group, and the finer colored lines represent the 95% CIs for each group.

Change in HbA1c by group; two subsets can be created based on likely improvement Can we predict future improvement in glycaemic control?. Diabetic Medicine 25 (2),

It is inappropriately intensive treatment “ not good glycemic control ” which increase the risk.

We have to individualize diabetes treatment. Most of the time side effects are a result of confectionary treatments.

So we should achive as low HbA1c as possible in an individual patient without causing hypoglycemia and weight gain. We have the tools.